Status: Not yet recruiting
Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism
The purpose of this study is to measure outcomes using intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 40-75Biological sex: AllType: InterventionalSponsor: Apeiron Research CenterUpdated: Mar 5, 2025
Eligibility criteria
Participants aged 40-75 years old with a diagnosis of PD or PPS (DLB, PSP, MSA,... [+34]
Other non-PD/PPS Parkinsonism (e.g., drug-induced, vascular parkinsonism) [+29]